Skip to contentA
Axim Biotechnologies, Inc.
A
AXIMAxim Biotechnologies, Inc. Q1 2021 · 10-Q
Revenue$32.65K$32.65Kno prior Q1 2020 on file Net Income-$864.54K-$864.54KN/M vs Q1 2020 EPS Diluted-$0.01-$0.01N/M vs Q1 2020 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Axim Biotechnologies, Inc. · CIK 1514946 · Engraved from SEC EDGAR
Operating Cash Flow-$565,461N/M Margins · derivedGross margin100.0%
Operating margin-2658.6%
Net margin-2648.0%
ended Mar 31, 2021 · filed May 24, 2021 · 54 d after period end